Keyphrases
Irritable Bowel Syndrome
100%
Functional Constipation
28%
Opioid-induced Constipation
27%
Placebo
25%
Chronic Noncancer Pain
23%
Constipation
20%
Abdominal Pain
16%
Systemic Sclerosis
16%
Opioids
15%
Laxatives
14%
Gastrointestinal Diseases
14%
Over-the-counter
12%
Randomized Controlled Trial
11%
Bowel Dysfunction
11%
Linaclotide
11%
Eluxadoline
11%
Cognitive Behavioral Therapy
11%
Methylnaltrexone
10%
Constipation Symptoms
10%
Pharmacological Therapy
10%
Pooled Analysis
9%
Plecanatide
9%
Bloating
8%
Tegaserod
8%
Treatment Options
8%
Quality of Life
8%
Abdominal Symptoms
8%
Moderate to Severe
8%
Randomized Placebo-controlled Trial
7%
Adverse Events
7%
Clinical Trials
7%
Naldemedine
7%
Treatment Strategy
7%
Opioid Antagonist
7%
Evidence-based Treatment
6%
Diarrhea
6%
Symptom Control
6%
Loperamide
6%
Naloxegol
6%
Cost-effectiveness
6%
Pain Syndrome
6%
Chronic Abdominal Pain
6%
Prescription Drugs
6%
Healthcare Professionals
6%
Treatment Outcome
6%
Symptom Improvement
6%
Lubiprostone
5%
Symptom Severity
5%
Gastroenterologist
5%
Fecal Incontinence
5%
Pharmacology, Toxicology and Pharmaceutical Science
Irritable Colon
76%
Constipation
65%
Opiate
36%
Placebo
34%
Diarrhea
18%
Abdominal Pain
13%
Randomized Controlled Trial
13%
Linaclotide
11%
Eluxadoline
11%
Methylnaltrexone
10%
Pharmacotherapy
10%
Disease
9%
Bloating
9%
Adverse Event
9%
Plecanatide
8%
Tegaserod
7%
Gastrointestinal Symptom
7%
Naldemedine
7%
Probiotic Agent
6%
Clinical Trial
6%
Pain
6%
Loperamide
6%
Naloxegol
6%
Cancer Pain
6%
Laxative
6%
Lubiprostone
5%
Narcotic Antagonist
5%
Medicine and Dentistry
Irritable Bowel Syndrome
56%
Constipation
38%
Abdominal Pain
15%
Placebo
15%
Opiate
14%
Systemic Scleroderma
12%
Bloating
10%
Diarrhea
9%
17 Methylnaltrexone
9%
Health Care Cost
9%
Quality of Life
8%
Diseases
8%
Laxative
7%
Cognitive Behavioral Therapy
7%
Randomized Controlled Trial
7%
Chronic Constipation
7%
Tegaserod
7%
Post-Hoc Analysis
7%
Pain
7%
Pooled Analysis
6%
Cost-Effectiveness Analysis
6%
Linaclotide
5%
Prescription Drug
5%
Systematic Review
5%
Gastrointestinal Distress
5%